These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

482 related items for PubMed ID: 24877186

  • 1. Evaluation of preventive cardiovascular pharmacotherapy after coronary artery bypass graft surgery.
    Barry AR, Koshman SL, Norris CM, Ross DB, Pearson GJ.
    Pharmacotherapy; 2014 May; 34(5):464-72. PubMed ID: 24877186
    [Abstract] [Full Text] [Related]

  • 2. Utilization of Evidence-Based Secondary Prevention Medications at the Time of Discharge in Patients with Acute Coronary Syndrome (ACS) in Qatar.
    El-Hajj MS, Saad A, Al-Suwaidi J, Al-Marridi WZ, Elkhalifa DH, Mohamed AA, Mahfoud ZR.
    Curr Vasc Pharmacol; 2016 May; 14(4):394-403. PubMed ID: 26916397
    [Abstract] [Full Text] [Related]

  • 3. Under-use of secondary prevention medication in acute coronary syndrome patients treated with in-hospital coronary artery bypass graft surgery.
    Looi KL, Chow KL, Looi JL, Lee M, Halliday S, White H, Ellis C.
    N Z Med J; 2011 Sep 23; 124(1343):18-27. PubMed ID: 21964009
    [Abstract] [Full Text] [Related]

  • 4. Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge.
    Lee HY, Cooke CE, Robertson TA.
    J Manag Care Pharm; 2008 Apr 23; 14(3):271-80. PubMed ID: 18439049
    [Abstract] [Full Text] [Related]

  • 5. Secondary prevention following coronary artery bypass grafting has improved but remains sub-optimal: the need for targeted follow-up.
    Turley AJ, Roberts AP, Morley R, Thornley AR, Owens WA, de Belder MA.
    Interact Cardiovasc Thorac Surg; 2008 Apr 23; 7(2):231-4. PubMed ID: 18234766
    [Abstract] [Full Text] [Related]

  • 6. Should all patients be treated with an angiotensin-converting enzyme inhibitor after coronary artery bypass graft surgery? The impact of angiotensin-converting enzyme inhibitors, statins, and β-blockers after coronary artery bypass graft surgery.
    Kalavrouziotis D, Buth KJ, Cox JL, Baskett RJ.
    Am Heart J; 2011 Nov 23; 162(5):836-43. PubMed ID: 22093199
    [Abstract] [Full Text] [Related]

  • 7. Medical Therapy Utilization and Long-Term Outcomes Following Percutaneous Coronary Intervention: Five-Year Results From the Veterans Affairs Clinical Assessment, Reporting, and Tracking System Program.
    Xie JX, Gunzburger EC, Kaun L, Plomondon ME, Barón AE, Waldo SW, Virani SS, Maddox TM, Mavromatis K.
    Circ Cardiovasc Qual Outcomes; 2019 Nov 23; 12(11):e005455. PubMed ID: 31665896
    [Abstract] [Full Text] [Related]

  • 8. Self-reported use of evidence-based medicine and smoking cessation 6 - 9 months after acute coronary syndrome: a single-centre perspective.
    Griffiths B, Lesosky M, Ntsekhe M.
    S Afr Med J; 2014 Jun 17; 104(7):483-7. PubMed ID: 25214049
    [Abstract] [Full Text] [Related]

  • 9. Use of cardiovascular medical therapy among patients undergoing coronary artery bypass graft surgery: results from the ROSETTA-CABG registry.
    Okrainec K, Pilote L, Platt R, Eisenberg MJ.
    Can J Cardiol; 2006 Aug 17; 22(10):841-7. PubMed ID: 16957801
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Rationale and design of a randomized cluster trial to improve guideline-adherence of secondary preventive drugs prescription after coronary artery bypass grafting in China: Measurement and Improvement Studies of Surgical Coronary Revascularization: Secondary Prevention (MISSION-1) Study.
    Rao C, Du J, Li X, Li J, Zhang H, Zhao Y, Hu S, Jiang L, Zheng Z, MISSION-1 Collaborative Group.
    Am Heart J; 2016 Aug 17; 178():9-18. PubMed ID: 27502847
    [Abstract] [Full Text] [Related]

  • 12. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey.
    Yusuf S, Islam S, Chow CK, Rangarajan S, Dagenais G, Diaz R, Gupta R, Kelishadi R, Iqbal R, Avezum A, Kruger A, Kutty R, Lanas F, Lisheng L, Wei L, Lopez-Jaramillo P, Oguz A, Rahman O, Swidan H, Yusoff K, Zatonski W, Rosengren A, Teo KK, Prospective Urban Rural Epidemiology (PURE) Study Investigators.
    Lancet; 2011 Oct 01; 378(9798):1231-43. PubMed ID: 21872920
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Longitudinal persistence with secondary prevention therapies relative to patient risk after myocardial infarction.
    Shore S, Jones PG, Maddox TM, Bradley SM, Stolker JM, Arnold SV, Parashar S, Peterson P, Bhatt DL, Spertus J, Ho PM.
    Heart; 2015 May 15; 101(10):800-7. PubMed ID: 25801001
    [Abstract] [Full Text] [Related]

  • 17. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients.
    Naderi SH, Bestwick JP, Wald DS.
    Am J Med; 2012 Sep 15; 125(9):882-7.e1. PubMed ID: 22748400
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Do practice gaps exist in evidence-based medication prescription at hospital discharge in patients undergoing coronary artery bypass surgery & coronary angioplasty?
    Pereira P, Kapoor A, Sinha A, Agarwal SK, Pande S, Khanna R, Srivastava N, Kumar S, Garg N, Tewari S, Goel P.
    Indian J Med Res; 2017 Dec 15; 146(6):722-729. PubMed ID: 29664030
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.